Alirocumab Reduces Total Hospitalizations and Increases Days Alive and Out of Hospital in the ODYSSEY OUTCOMES Trial. [electronic resource]
Producer: 20200706Description: e005858 p. digitalISSN:- 1941-7705
- Acute Coronary Syndrome -- blood
- Angina, Unstable -- blood
- Antibodies, Monoclonal, Humanized -- adverse effects
- Anticholesteremic Agents -- adverse effects
- Biomarkers -- blood
- Cholesterol, HDL -- blood
- Cholesterol, LDL -- blood
- Drug Therapy, Combination
- Dyslipidemias -- blood
- Hospital Mortality
- Humans
- Hydroxymethylglutaryl-CoA Reductase Inhibitors -- therapeutic use
- Myocardial Infarction -- blood
- Patient Admission
- Patient Readmission
- Risk Assessment
- Risk Factors
- Time Factors
- Treatment Outcome
No physical items for this record
Publication Type: Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.